Skip to main content
Erschienen in: Surgery Today 1/2019

30.08.2018 | Original Article

Prognostic factors for cytology-positive gastric cancer

verfasst von: Shunji Endo, Masakazu Ikenaga, Katsuya Ohta, Masami Ueda, Yujiro Tsuda, Ryo Kato, Hiroaki Itakura, Jin Matsuyama, Kazuhiro Nishikawa, Terumasa Yamada

Erschienen in: Surgery Today | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Positive peritoneal lavage cytology for gastric carcinoma cells (CY1) is considered distant metastasis and is classified as Stage IV. However, patients with CY1 comprise a heterogeneous population, and their prognosis varies greatly. The prognostic factors for gastric cancer patients with CY1 were retrospectively reviewed.

Methods

The participants were 80 gastric cancer patients with CY1 in our institution encountered between 2005 and 2017. Prognostic factors were analyzed using univariate and multivariate analyses.

Results

The operative procedure was distal gastrectomy for 30 patients, total gastrectomy for 27 patients, staging laparoscopy for 10 patients, gastrojejunostomy for 8 patients, and probe laparotomy for 5 patients. Other distant metastases were recognized in 36 patients. A multivariate analysis revealed that other distant metastases were the strongest independent risk factor for the overall survival (p < 0.0001). When the cohort was limited to CY1 patients without other distant metastases, cN2–3 (p = 0.01), the prognostic nutritional index (PNI) < 40 (p = 0.02) and Type 4 (p = 0.03) were independent risk factors according to a multivariate analysis. The survivals of patients with cN2–3 or PNI < 40 after gastrectomy were equivalent to those with other distant metastases, as assessed by log-rank analyses.

Conclusions

The prognoses of CY1 gastric cancer patients with cN2–3 or PNI < 40 were poor, even after gastrectomy.
Literatur
3.
Zurück zum Zitat Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma, the 15th edition (in Japanese). Tokyo: Kanehara; 2017. Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma, the 15th edition (in Japanese). Tokyo: Kanehara; 2017.
4.
Zurück zum Zitat Brierley JD, Gospodarowicz MK, Wittekind C. TNM classification of malignant tumours, the eighth edition. Oxford: Wiley Blackwell; 2017. Brierley JD, Gospodarowicz MK, Wittekind C. TNM classification of malignant tumours, the eighth edition. Oxford: Wiley Blackwell; 2017.
5.
Zurück zum Zitat Association Japanese Gastric Cancer. Gastric Cancer Treatment Guidelines, 5th ed. Tokyo: Kanehara; 2018 (in Japanese). Association Japanese Gastric Cancer. Gastric Cancer Treatment Guidelines, 5th ed. Tokyo: Kanehara; 2018 (in Japanese).
6.
Zurück zum Zitat Kodera Y, Ito S, Mochizuki Y, Kondo K, Koshikawa K, Suzuki N, et al. A phase II study of radical surgery followed by postoperative chemotherapy with S-1 for gastric carcinoma with free cancer cells in the peritoneal cavity (CCOG0301 study). Eur J Surg Oncol. 2009;35:1158–63.CrossRef Kodera Y, Ito S, Mochizuki Y, Kondo K, Koshikawa K, Suzuki N, et al. A phase II study of radical surgery followed by postoperative chemotherapy with S-1 for gastric carcinoma with free cancer cells in the peritoneal cavity (CCOG0301 study). Eur J Surg Oncol. 2009;35:1158–63.CrossRef
7.
Zurück zum Zitat Onodera T, Goseki N, Kosaki G. Prognostic nutritional index in gastrointestinal surgery of malnourished cancer patients (in Japanese with English abstract). Nihon Geka Gakkai Zasshi (J Jpn Surg Society). 1984;85:1001–5. Onodera T, Goseki N, Kosaki G. Prognostic nutritional index in gastrointestinal surgery of malnourished cancer patients (in Japanese with English abstract). Nihon Geka Gakkai Zasshi (J Jpn Surg Society). 1984;85:1001–5.
8.
Zurück zum Zitat Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the eastern cooperative oncology group. Am J Clin Oncol. 1982;5:649–55.CrossRef Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the eastern cooperative oncology group. Am J Clin Oncol. 1982;5:649–55.CrossRef
10.
Zurück zum Zitat Lee SD, Ryu KW, Eom BW, Lee JH, Kook MC, Kim YW, et al. Prognostic significance of peritoneal washing cytology in patients with gastric cancer. Br J Surg. 2012;99:397–403.CrossRef Lee SD, Ryu KW, Eom BW, Lee JH, Kook MC, Kim YW, et al. Prognostic significance of peritoneal washing cytology in patients with gastric cancer. Br J Surg. 2012;99:397–403.CrossRef
11.
Zurück zum Zitat Yoshida K, Yamaguchi K, Okumura N, Tanahashi T, Kodera Y. Is conversion therapy possible in stage IV gastric cancer: the proposal of new biological categories of classification. Gastric Cancer. 2016;19:329–38.CrossRef Yoshida K, Yamaguchi K, Okumura N, Tanahashi T, Kodera Y. Is conversion therapy possible in stage IV gastric cancer: the proposal of new biological categories of classification. Gastric Cancer. 2016;19:329–38.CrossRef
12.
Zurück zum Zitat Nakagohri T, Yoneyama Y, Kinoshita T, Konishi M, Inoue K, Takahashi S. Prognostic significance of peritoneal washing cytology in patients with potentially resectable gastric cancer. Hepatogastroenterology. 2008;55:1913–5.PubMed Nakagohri T, Yoneyama Y, Kinoshita T, Konishi M, Inoue K, Takahashi S. Prognostic significance of peritoneal washing cytology in patients with potentially resectable gastric cancer. Hepatogastroenterology. 2008;55:1913–5.PubMed
13.
Zurück zum Zitat Nishikawa K, Fujitani K, Endo S, Kawada J, Hirao M, Hamakawa T, et al. Is gastrectomy for CY1 gastric cancer truly essential? [abstract]. In 90th Annual Meeting of the Japanese Gastric Cancer Association program: 2018 Mar 7–9: Yokohama. Japan: Abstract PP230. Nishikawa K, Fujitani K, Endo S, Kawada J, Hirao M, Hamakawa T, et al. Is gastrectomy for CY1 gastric cancer truly essential? [abstract]. In 90th Annual Meeting of the Japanese Gastric Cancer Association program: 2018 Mar 7–9: Yokohama. Japan: Abstract PP230.
14.
Zurück zum Zitat Fujitani K, Yang HK, Mizusawa J, Kim YW, Terashima M, Han SU, et al. Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial. Lancet Oncol. 2016;17:309–18.CrossRef Fujitani K, Yang HK, Mizusawa J, Kim YW, Terashima M, Han SU, et al. Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial. Lancet Oncol. 2016;17:309–18.CrossRef
15.
Zurück zum Zitat Yamamoto M, Kawano H, Yamaguchi S, Egashira A, Minami K, Taguchi K, et al. Comparison of neoadjuvant chemotherapy to surgery followed by adjuvant chemotherapy in Japanese patients with peritoneal lavage cytology positive for gastric carcinoma. Anticancer Res. 2015;35:4859–63.PubMed Yamamoto M, Kawano H, Yamaguchi S, Egashira A, Minami K, Taguchi K, et al. Comparison of neoadjuvant chemotherapy to surgery followed by adjuvant chemotherapy in Japanese patients with peritoneal lavage cytology positive for gastric carcinoma. Anticancer Res. 2015;35:4859–63.PubMed
16.
Zurück zum Zitat Fukuchi M, Mochiki E, Ishiguro T, Ogura T, Sobajima J, Kumagai Y, et al. Prognostic factors for gastric cancer with cancer cells in the peritoneal cavity. Anticancer Res. 2016;36:2481–5.CrossRef Fukuchi M, Mochiki E, Ishiguro T, Ogura T, Sobajima J, Kumagai Y, et al. Prognostic factors for gastric cancer with cancer cells in the peritoneal cavity. Anticancer Res. 2016;36:2481–5.CrossRef
17.
Zurück zum Zitat Kano K, Aoyama T, Maezawa Y, Nakajima T, Ikeda K, Yamada T, et al. The survival and prognosticators of peritoneal cytology-positive gastric cancer patients who received upfront gastrectomy and subsequent S-1 chemotherapy. Int J Clin Oncol. 2017;22:887–96.CrossRef Kano K, Aoyama T, Maezawa Y, Nakajima T, Ikeda K, Yamada T, et al. The survival and prognosticators of peritoneal cytology-positive gastric cancer patients who received upfront gastrectomy and subsequent S-1 chemotherapy. Int J Clin Oncol. 2017;22:887–96.CrossRef
18.
Zurück zum Zitat Saito H, Kihara K, Kuroda H, Matsunaga T, Tatebe S, Ikeguchi M. Surgical outcomes for gastric cancer patients with intraperitoneal free cancer cell, but no macroscopic peritoneal metastasis. J Surg Oncol. 2011;104:534–7.CrossRef Saito H, Kihara K, Kuroda H, Matsunaga T, Tatebe S, Ikeguchi M. Surgical outcomes for gastric cancer patients with intraperitoneal free cancer cell, but no macroscopic peritoneal metastasis. J Surg Oncol. 2011;104:534–7.CrossRef
19.
Zurück zum Zitat Tsuburaya A, Mizusawa J, Tanaka Y, Fukushima N, Nashimoto A, Sasako M. Neoadjuvant chemotherapy with S-1 and cisplatin followed by D2 gastrectomy with para-aortic lymph node dissection for gastric cancer with extensive lymph node metastasis. Br J Surg. 2014;101:653–60.CrossRef Tsuburaya A, Mizusawa J, Tanaka Y, Fukushima N, Nashimoto A, Sasako M. Neoadjuvant chemotherapy with S-1 and cisplatin followed by D2 gastrectomy with para-aortic lymph node dissection for gastric cancer with extensive lymph node metastasis. Br J Surg. 2014;101:653–60.CrossRef
20.
Zurück zum Zitat Noda S, Yashiro M, Toyokawa T, Morimoto J, Shinto O, Muguruma K. Borrmann’s macroscopic criteria and p-Smad2 expression are useful predictive prognostic markers for cytology-positive gastric cancer patients without overt peritoneal metastasis. Ann Surg Oncol. 2011;18:3718–25.CrossRef Noda S, Yashiro M, Toyokawa T, Morimoto J, Shinto O, Muguruma K. Borrmann’s macroscopic criteria and p-Smad2 expression are useful predictive prognostic markers for cytology-positive gastric cancer patients without overt peritoneal metastasis. Ann Surg Oncol. 2011;18:3718–25.CrossRef
21.
Zurück zum Zitat Fukagawa T, Katai H, Saka M, Morita S, Sasajima Y, Taniguchi H, et al. Significance of lavage cytology in advanced gastric cancer patients. World J Surg. 2010;34(3):563–8.CrossRef Fukagawa T, Katai H, Saka M, Morita S, Sasajima Y, Taniguchi H, et al. Significance of lavage cytology in advanced gastric cancer patients. World J Surg. 2010;34(3):563–8.CrossRef
22.
Zurück zum Zitat Kano Y, Kosugi S, Ishikawa T, Otani T, Muneoka Y, Sato Y, et al. Prognostic significance of peritoneal lavage cytology at three cavities in patients with gastric cancer. Surgery. 2015;158:1581–9.CrossRef Kano Y, Kosugi S, Ishikawa T, Otani T, Muneoka Y, Sato Y, et al. Prognostic significance of peritoneal lavage cytology at three cavities in patients with gastric cancer. Surgery. 2015;158:1581–9.CrossRef
23.
Zurück zum Zitat Nishimura T, Iwasa S, Nagashima K, Okita N, Takashima A, Honma Y, et al. Irinotecan monotherapy as third-line treatment for advanced gastric cancer refractory to fluoropyrimidines, platinum, and taxanes. Gastric Cancer. 2017;20:655–62.CrossRef Nishimura T, Iwasa S, Nagashima K, Okita N, Takashima A, Honma Y, et al. Irinotecan monotherapy as third-line treatment for advanced gastric cancer refractory to fluoropyrimidines, platinum, and taxanes. Gastric Cancer. 2017;20:655–62.CrossRef
24.
Zurück zum Zitat Crumley AB, Stuart RC, McKernan M, McMillan DC. Is hypoalbuminemia an independent prognostic factor in patients with gastric cancer? World J Surg. 2010;34:2393–8.CrossRef Crumley AB, Stuart RC, McKernan M, McMillan DC. Is hypoalbuminemia an independent prognostic factor in patients with gastric cancer? World J Surg. 2010;34:2393–8.CrossRef
25.
Zurück zum Zitat Chen XL, Xue L, Wang W, Chen HN, Zhang WH, Liu K, et al. Prognostic significance of the combination of preoperative hemoglobin, albumin, lymphocyte and platelet in patients with gastric carcinoma: a retrospective cohort study. Oncotarget. 2015;6:41370–82.PubMedPubMedCentral Chen XL, Xue L, Wang W, Chen HN, Zhang WH, Liu K, et al. Prognostic significance of the combination of preoperative hemoglobin, albumin, lymphocyte and platelet in patients with gastric carcinoma: a retrospective cohort study. Oncotarget. 2015;6:41370–82.PubMedPubMedCentral
Metadaten
Titel
Prognostic factors for cytology-positive gastric cancer
verfasst von
Shunji Endo
Masakazu Ikenaga
Katsuya Ohta
Masami Ueda
Yujiro Tsuda
Ryo Kato
Hiroaki Itakura
Jin Matsuyama
Kazuhiro Nishikawa
Terumasa Yamada
Publikationsdatum
30.08.2018
Verlag
Springer Singapore
Erschienen in
Surgery Today / Ausgabe 1/2019
Print ISSN: 0941-1291
Elektronische ISSN: 1436-2813
DOI
https://doi.org/10.1007/s00595-018-1704-1

Weitere Artikel der Ausgabe 1/2019

Surgery Today 1/2019 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.